Abstract

FERNANDEZ-HERNANDEZ, Juan A. et al. Recent advances in gastrointestinal stromal tumors: Where are we going?. Cir. cir. [online]. 2022, vol.90, n.2, pp.267-277.  Epub May 02, 2022. ISSN 2444-054X.  https://doi.org/10.24875/ciru.20001318.

Gastrointestinal Stromal Sarcomas (GIST) are mesenchymal neoplasms whose incidence accounts for 1-2% of digestive tumors, being located in the stomach (55-60%) and small intestine (30%). The advances in its knowledge and management succeeded in the last years have being spectacular. This review aims to summarize the most important of them for surgeons. We identified four areas of interest: molecular oncology, laparoscopic approach, management of GIST located at unusual locations, and management of advanced GIST. Advances in the field of molecular oncology lead to the discovery of new oncogenic mutations making the term Wil Type GIST obsolete. Moreover, these advances allow for the development of 2 new drugs: Avapritinib and Ripretinib, that added to the previous 3 commercially available drugs (imatinib, sunitinib and regorafenib) make possible the management of GIST with resistant mutations. The principles of the surgical management of primary GIST are well stablished which laparoscopic approach must accomplish. This approach is limited by 2 main factors: location and size. The diagnosis of GIST in unusual locations as esophagus, duodenum, rectum of out of the gastrointestinal tract (EGIST), implies an extraordinary therapeutic challenge, being imperative to manage them by surgeons and oncologist among others in the setting of a multidisciplinary team. The management of advanced/metastatic GIST has changed in a revolutionary fashion because surgery is now part of its treatment as adjuvant to tyrosine kinase inhibitors.

Keywords : Gastrointestinal stromal tumors (GIST); Tyrosine kinase inhibitors (TKI); Imatinib; Laparoscopy; Multidisciplinary teams.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )